<p><strong>Pregnancy&nbsp;</strong>Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).<br />
<br />
<strong>Lactation</strong>: Advise women not to breastfeed during treatment with Pemetrexed and for 1 week after the final dose.</p>